Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first phase I/IIa glioblastoma trial
Oncolytic virotherapy may be a means of improving the dismal prognosis of malignant brain tumors. The rat H-1 parvovirus (H-1PV) suppresses tumors in preclinical glioma models, through both direct oncolysis and stimulation of anticancer immune responses. This was the basis of ParvOryx01, the first p...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
24 August 2017
|
| In: |
Molecular therapy
Year: 2017, Jahrgang: 25, Heft: 12, Pages: 2620-2634 |
| ISSN: | 1525-0024 |
| DOI: | 10.1016/j.ymthe.2017.08.016 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1016/j.ymthe.2017.08.016 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S1525001617303787 
|
| Verfasserangaben: | Karsten Geletneky, Jacek Hajda, Assia L. Angelova, Barbara Leuchs, David Capper, Andreas J. Bartsch, Jan-Oliver Neumann, Tilman Schöning, Johannes Hüsing, Birgit Beelte, Irina Kiprianova, Mandy Roscher, Rauf Bhat, Andreas von Deimling, Wolfgang Brück, Alexandra Just, Veronika Frehtman, Stephanie Löbhard, Elena Terletskaia-Ladwig, Jeremy Fry, Karin Jochims, Volker Daniel, Ottheinz Krebs, Michael Dahm, Bernard Huber, Andreas Unterberg, and Jean Rommelaere |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1572510722 | ||
| 003 | DE-627 | ||
| 005 | 20240316100347.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180502s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ymthe.2017.08.016 |2 doi | |
| 035 | |a (DE-627)1572510722 | ||
| 035 | |a (DE-576)502510722 | ||
| 035 | |a (DE-599)BSZ502510722 | ||
| 035 | |a (OCoLC)1341008009 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Geletneky, Karsten |d 1964- |e VerfasserIn |0 (DE-588)123632862 |0 (DE-627)706375475 |0 (DE-576)293799326 |4 aut | |
| 245 | 1 | 0 | |a Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first phase I/IIa glioblastoma trial |c Karsten Geletneky, Jacek Hajda, Assia L. Angelova, Barbara Leuchs, David Capper, Andreas J. Bartsch, Jan-Oliver Neumann, Tilman Schöning, Johannes Hüsing, Birgit Beelte, Irina Kiprianova, Mandy Roscher, Rauf Bhat, Andreas von Deimling, Wolfgang Brück, Alexandra Just, Veronika Frehtman, Stephanie Löbhard, Elena Terletskaia-Ladwig, Jeremy Fry, Karin Jochims, Volker Daniel, Ottheinz Krebs, Michael Dahm, Bernard Huber, Andreas Unterberg, and Jean Rommelaere |
| 264 | 1 | |c 24 August 2017 | |
| 300 | |a 15 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 02.05.2018 | ||
| 520 | |a Oncolytic virotherapy may be a means of improving the dismal prognosis of malignant brain tumors. The rat H-1 parvovirus (H-1PV) suppresses tumors in preclinical glioma models, through both direct oncolysis and stimulation of anticancer immune responses. This was the basis of ParvOryx01, the first phase I/IIa clinical trial of an oncolytic parvovirus in recurrent glioblastoma patients. H-1PV (escalating dose) was administered via intratumoral or intravenous injection. Tumors were resected 9 days after treatment, and virus was re-administered around the resection cavity. Primary endpoints were safety and tolerability, virus distribution, and maximum tolerated dose (MTD). Progression-free and overall survival and levels of viral and immunological markers in the tumor and peripheral blood were also investigated. H-1PV treatment was safe and well tolerated, and no MTD was reached. The virus could cross the blood-brain/tumor barrier and spread widely through the tumor. It showed favorable pharmacokinetics, induced antibody formation in a dose-dependent manner, and triggered specific T cell responses. Markers of virus replication, microglia/macrophage activation, and cytotoxic T cell infiltration were detected in infected tumors, suggesting that H-1PV may trigger an immunogenic stimulus. Median survival was extended in comparison with recent meta-analyses. Altogether, ParvOryx01 results provide an impetus for further H-1PV clinical development. | ||
| 650 | 4 | |a clinical trial | |
| 650 | 4 | |a glioblastoma | |
| 650 | 4 | |a oncolytic parvovirus | |
| 650 | 4 | |a tumor microenvironment | |
| 700 | 1 | |a Hajda, Jacek |d 1970- |e VerfasserIn |0 (DE-588)12349656X |0 (DE-627)082589542 |0 (DE-576)293733341 |4 aut | |
| 700 | 1 | |a Beelte, Birgit |e VerfasserIn |0 (DE-588)1159389748 |0 (DE-627)1021619590 |0 (DE-576)504561650 |4 aut | |
| 700 | 1 | |a Capper, David |d 1979- |e VerfasserIn |0 (DE-588)133950751 |0 (DE-627)558829902 |0 (DE-576)300212402 |4 aut | |
| 700 | 1 | |a Bartsch, Andreas J. |d 1968- |e VerfasserIn |0 (DE-588)122450191 |0 (DE-627)08195073X |0 (DE-576)250275260 |4 aut | |
| 700 | 1 | |a Neumann, Jan-Oliver |d 1976- |e VerfasserIn |0 (DE-588)131972472 |0 (DE-627)516327194 |0 (DE-576)298869276 |4 aut | |
| 700 | 1 | |a Schöning, Tilman |d 1972- |e VerfasserIn |0 (DE-588)140330836 |0 (DE-627)617702489 |0 (DE-576)316456705 |4 aut | |
| 700 | 1 | |a Hüsing, Johannes |d 1965- |e VerfasserIn |0 (DE-588)124519687 |0 (DE-627)36339270X |0 (DE-576)294211306 |4 aut | |
| 700 | 1 | |a Deimling, Andreas von |d 1959- |e VerfasserIn |0 (DE-588)103034115X |0 (DE-627)735093946 |0 (DE-576)378138065 |4 aut | |
| 700 | 1 | |a Daniel, Volker |e VerfasserIn |0 (DE-588)1058939513 |0 (DE-627)79784418X |0 (DE-576)166309168 |4 aut | |
| 700 | 1 | |a Unterberg, Andreas |e VerfasserIn |0 (DE-588)1032681187 |0 (DE-627)738641200 |0 (DE-576)168441233 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular therapy |d Amsterdam : Elsevier, 2000 |g 25(2017), 12, Seite 2620-2634 |h Online-Ressource |w (DE-627)320415198 |w (DE-600)2001818-6 |w (DE-576)104344695 |x 1525-0024 |7 nnas |a Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first phase I/IIa glioblastoma trial |
| 773 | 1 | 8 | |g volume:25 |g year:2017 |g number:12 |g pages:2620-2634 |g extent:15 |a Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first phase I/IIa glioblastoma trial |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ymthe.2017.08.016 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1525001617303787 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180502 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 1032681187 |a Unterberg, Andreas |m 1032681187:Unterberg, Andreas |d 910000 |d 911200 |e 910000PU1032681187 |e 911200PU1032681187 |k 0/910000/ |k 1/910000/911200/ |p 26 | ||
| 998 | |g 1058939513 |a Daniel, Volker |m 1058939513:Daniel, Volker |p 22 | ||
| 998 | |g 103034115X |a Deimling, Andreas von |m 103034115X:Deimling, Andreas von |d 910000 |d 912000 |e 910000PD103034115X |e 912000PD103034115X |k 0/910000/ |k 1/910000/912000/ |p 14 | ||
| 998 | |g 124519687 |a Hüsing, Johannes |m 124519687:Hüsing, Johannes |d 910000 |d 913000 |e 910000PH124519687 |e 913000PH124519687 |k 0/910000/ |k 1/910000/913000/ |p 9 | ||
| 998 | |g 140330836 |a Schöning, Tilman |m 140330836:Schöning, Tilman |d 910000 |e 910000PS140330836 |k 0/910000/ |p 8 | ||
| 998 | |g 131972472 |a Neumann, Jan-Oliver |m 131972472:Neumann, Jan-Oliver |d 910000 |d 911200 |e 910000PN131972472 |e 911200PN131972472 |k 0/910000/ |k 1/910000/911200/ |p 7 | ||
| 998 | |g 122450191 |a Bartsch, Andreas J. |m 122450191:Bartsch, Andreas J. |d 50000 |e 50000PB122450191 |k 0/50000/ |p 6 | ||
| 998 | |g 133950751 |a Capper, David |m 133950751:Capper, David |p 5 | ||
| 998 | |g 1159389748 |a Beelte, Birgit |m 1159389748:Beelte, Birgit |d 910000 |d 913000 |e 910000PB1159389748 |e 913000PB1159389748 |k 0/910000/ |k 1/910000/913000/ |p 10 | ||
| 998 | |g 12349656X |a Hajda, Jacek |m 12349656X:Hajda, Jacek |d 910000 |d 913000 |e 910000PH12349656X |e 913000PH12349656X |k 0/910000/ |k 1/910000/913000/ |p 2 | ||
| 998 | |g 123632862 |a Geletneky, Karsten |m 123632862:Geletneky, Karsten |d 910000 |d 911200 |e 910000PG123632862 |e 911200PG123632862 |k 0/910000/ |k 1/910000/911200/ |p 1 |x j | ||
| 999 | |a KXP-PPN1572510722 |e 3007733030 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1572510722","id":{"eki":["1572510722"],"doi":["10.1016/j.ymthe.2017.08.016"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"name":{"displayForm":["Karsten Geletneky, Jacek Hajda, Assia L. Angelova, Barbara Leuchs, David Capper, Andreas J. Bartsch, Jan-Oliver Neumann, Tilman Schöning, Johannes Hüsing, Birgit Beelte, Irina Kiprianova, Mandy Roscher, Rauf Bhat, Andreas von Deimling, Wolfgang Brück, Alexandra Just, Veronika Frehtman, Stephanie Löbhard, Elena Terletskaia-Ladwig, Jeremy Fry, Karin Jochims, Volker Daniel, Ottheinz Krebs, Michael Dahm, Bernard Huber, Andreas Unterberg, and Jean Rommelaere"]},"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"24 August 2017"}],"note":["Gesehen am 02.05.2018"],"language":["eng"],"person":[{"role":"aut","family":"Geletneky","display":"Geletneky, Karsten","given":"Karsten"},{"given":"Jacek","family":"Hajda","role":"aut","display":"Hajda, Jacek"},{"family":"Beelte","role":"aut","display":"Beelte, Birgit","given":"Birgit"},{"given":"David","family":"Capper","role":"aut","display":"Capper, David"},{"given":"Andreas J.","display":"Bartsch, Andreas J.","role":"aut","family":"Bartsch"},{"given":"Jan-Oliver","family":"Neumann","role":"aut","display":"Neumann, Jan-Oliver"},{"display":"Schöning, Tilman","family":"Schöning","role":"aut","given":"Tilman"},{"given":"Johannes","display":"Hüsing, Johannes","role":"aut","family":"Hüsing"},{"given":"Andreas von","display":"Deimling, Andreas von","role":"aut","family":"Deimling"},{"display":"Daniel, Volker","family":"Daniel","role":"aut","given":"Volker"},{"given":"Andreas","role":"aut","family":"Unterberg","display":"Unterberg, Andreas"}],"relHost":[{"language":["eng"],"note":["Gesehen am 28.05.2020"],"pubHistory":["1.2000 -"],"type":{"bibl":"periodical","media":"Online-Ressource"},"recId":"320415198","id":{"issn":["1525-0024"],"eki":["320415198"],"zdb":["2001818-6"]},"origin":[{"publisher":"Elsevier ; Nature Publ. Group ; Acad. Press","dateIssuedDisp":"2000-","publisherPlace":"Amsterdam ; New York, NY ; Orlando, Fla.","dateIssuedKey":"2000"}],"corporate":[{"role":"isb","display":"American Society of Gene Therapy"}],"disp":"Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first phase I/IIa glioblastoma trialMolecular therapy","title":[{"subtitle":"official journal of the American Society of Gene Therapy","title_sort":"Molecular therapy","title":"Molecular therapy"}],"physDesc":[{"extent":"Online-Ressource"}],"part":{"text":"25(2017), 12, Seite 2620-2634","volume":"25","extent":"15","pages":"2620-2634","year":"2017","issue":"12"}}],"physDesc":[{"extent":"15 S."}],"title":[{"title_sort":"Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first phase I/IIa glioblastoma trial","title":"Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first phase I/IIa glioblastoma trial"}]} | ||
| SRT | |a GELETNEKYKONCOLYTICH2420 | ||